Treatment of mice with Ac-PHSCN-NH2 (ATN-161), a 5-mer-capped peptide derived from the synergistic region of fibronectin that blocks binding to integrin α5β1 and αvβ3, resulted in significant decreases in pERK, microvessel density, tumor cell proliferation in vivo, a significant dose-dependent decrease in tumor volume and skeletal and soft tissue metastases [360]. Here, FN1 is linked to neoplasm.